Literature DB >> 10029789

Warfarin therapy: evolving strategies in anticoagulation.

J D Horton1, B M Bushwick.   

Abstract

Warfarin is the oral anticoagulant most frequently used to control and prevent thromboembolic disorders. Prescribing the dose that both avoids hemorrhagic complications and achieves sufficient suppression of thrombosis requires a thorough understanding of the drug's unique pharmacology. Warfarin has a complex dose-response relationship that makes safe and effective use a challenge. For most indications, the dose is adjusted to maintain the patient's International Normalized Ratio (INR) at 2 to 3. Because of the delay in factor II (prothrombin) suppression, heparin is administered concurrently for four to five days to prevent thrombus propagation. Loading doses of warfarin are not warranted and may result in bleeding complications. Interactions with other drugs must be considered, and therapy in elderly patients requires careful management. Current dosing recommendations are reviewed, and practical guidelines for the optimal use of warfarin are provided.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029789

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  44 in total

1.  Bleeding incidence after oral surgery with continued oral anticoagulation.

Authors:  Wolfgang Eichhorn; Jens Burkert; Oliver Vorwig; Marco Blessmann; Georg Cachovan; Jürgen Zeuch; Marc Eichhorn; Max Heiland
Journal:  Clin Oral Investig       Date:  2011-12-13       Impact factor: 3.573

2.  Routine clotting screen has no role in the management of epistaxis: reiterating the point.

Authors:  M Shakeel; A Trinidade; T Iddamalgoda; M Supriya; K W Ah-See
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-04-09       Impact factor: 2.503

3.  Prevalence of Drug Combinations Increasing Bleeding Risk Among Warfarin Users With and Without Alzheimer's Disease.

Authors:  Heidi Taipale; Hanna Vuorikari; Antti Tanskanen; Marjaana Koponen; Jari Tiihonen; Raimo Kettunen; Sirpa Hartikainen
Journal:  Drugs Aging       Date:  2015-11       Impact factor: 3.923

4.  A review of warfarin dosing and monitoring.

Authors:  M Kuruvilla; C Gurk-Turner
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-07

Review 5.  Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice.

Authors:  Julie Kalabalik; Gail B Rattinger; Jesse Sullivan; Malgorzata Slugocki; Antonia Carbone; Anastasia Rivkin
Journal:  Drugs       Date:  2015-06       Impact factor: 9.546

6.  Prescribing warfarin appropriately to meet patient safety goals.

Authors:  Lekshmi Dharmarajan; T S Dharmarajan
Journal:  Am Health Drug Benefits       Date:  2008-07

7.  Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses.

Authors:  James K Burmester; Richard L Berg; Ingrid Glurich; Steven H Yale; John R Schmelzer; Michael D Caldwell
Journal:  Clin Med Res       Date:  2011-05-11

8.  Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin.

Authors:  Abrar Ahmed; John C Stephens; Carol A Kaus; William P Fay
Journal:  J Thromb Thrombolysis       Date:  2007-11-06       Impact factor: 2.300

Review 9.  Understanding the pharmacogenetic approach to warfarin dosing.

Authors:  Ingrid Glurich; James K Burmester; Michael D Caldwell
Journal:  Heart Fail Rev       Date:  2008-11-08       Impact factor: 4.214

10.  Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.

Authors:  Charles Frost; Sunil Nepal; Jessie Wang; Alan Schuster; Wonkyung Byon; Rebecca A Boyd; Zhigang Yu; Andrew Shenker; Yu Chen Barrett; Rogelio Mosqueda-Garcia; Frank Lacreta
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.